LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 4 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $101 | -16.5% | 85,336 | 0.0% | 0.00% | – |
| Q2 2023 | $121 | -9.7% | 85,336 | -4.2% | 0.00% | – |
| Q1 2023 | $134 | +28.8% | 89,100 | 0.0% | 0.00% | – |
| Q4 2022 | $104 | -99.9% | 89,100 | 0.0% | 0.00% | – |
| Q3 2022 | $101,000 | -11.4% | 89,100 | +23.1% | 0.00% | – |
| Q2 2022 | $114,000 | +21.3% | 72,400 | +18.5% | 0.00% | – |
| Q1 2022 | $94,000 | -34.3% | 61,091 | +4.6% | 0.00% | – |
| Q4 2021 | $143,000 | -51.0% | 58,391 | -49.5% | 0.00% | – |
| Q3 2021 | $292,000 | +90.8% | 115,691 | +115.3% | 0.00% | – |
| Q2 2021 | $153,000 | +48.5% | 53,731 | +22.7% | 0.00% | – |
| Q1 2021 | $103,000 | – | 43,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |